 
|
|
TB/HIV Working Group |
|
Home | TB/HIV Working Group | Meetings and Events | Key Issues in implementation | Publications | Contact Us
|
|
|
|
Meetings and Events
Core Group Meetings Meetings 2008 Archive  The Shack interior, AIDS 2008 Conference, Mexico |
From Mekong to Bali: the scale up of collaborative TB/HIV activities in Asia Pacific Region. 8-9 August, 2009, Bali, Indonesia.Catalyzing the implementation of collaborative HIV/TB activities in the Asia and Pacific regions is a key priority. This region has more than half of the global burden of TB and 12% of the global burden of HIV. To this end the meeting "From Mekong to Bali: scale up of HIV/TB collaborative activities in Asia Pacific" was organized by the World Health Organization (WHO) in collaboration with the HIV/TB Working Group of the Stop TB Partnership. 127 people from 18 countries participated in the meeting with representation from all high TB and HIV burden countries. Participants shared experiences and best practices to inform plans to accelerate the implementation of nation-wide scale up of collaborative HIV/TB activities. The meeting followed on from the first regional HIV/TB meeting held in the Mekong sub region in Ho Chi Minh City, Vietnam in October 2004. National TB and HIV program managers were joined by a broad range of AIDS and TB stakeholders active in the Asia and Pacific regions, members of the HIV/TB Working Group and representatives of bilateral and multilateral organizations, NGOS, and faith based organizations. The presentations and posters from the meeting are available below. The final meeting report will be available in due course.
TB/HIV at IAS 2009: Catalysing HIVT/TB Research: innovation, funding and networkingThe World Health Organization and the TB/HIV Working Group of the Stop TB Partnership in collaboration with the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE), International AIDS Society, Treatment Action Group and the Desmond Tutu HIV Centre of University of Cape Town organized a highly visible meeting in conjunction with the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town, South Africa on July 18-19, 2009. The meeting was attended by about 250 HIV researchers, activists and representatives from funding agencies. The meeting focused on critical TB/HIV issues in the areas of TB prevention, diagnosis and treatment, childhood TB and drug resistant TB. New and previously unreported data was shared, discussed and research priorities were defined. The research priority discussions during the meeting also informed the ongoing revision of the TB/HIV research priorities agenda. The outcome and key findings of the meeting were communicated to IAS conference delegates through a satellite symposium on July 21, 2009. Report of the meeting will be available soon. July 21, 2009Preventing TB in People Living with HIV: research priorities and way forward by Peter Godfrey-Faussett, UK TB in HIV-infected Children: addressing the research neglect by Soumya Swaminathan, India Drug resistance TB in People Living with HIV: research questions and priorities by Haileyesus Getahun, Switzerland Clinical challenges of diagnosing and treating TB in People Living with HIV: what next for research? By Prudence Ive, South Africa July 19, 2009Key note presentation Challenges on TB-HIV Research by Françoise Barré-Sinoussi, France Watch Dr. Barré-Sinoussi's plenary presentation  Research activism from HIV to TB by Mark Harrington, USA Session III: Childhood TB TB diagnosis in Children: experience with HIV-infected children by Anneke Hesseling, South Africa ARV TB drug experience in children: when and what to start? By Philippa Musoke, Uganda Mother to child transmission of TB: what do we know? By Amita Gupta, India Developing safer TB vaccines for children with HIV by Jerald Sadoff, USA Session IV: Drug resistance TB and HIV MDR, XDR TB and HIV: global data, approaches and operational research issues by Paul Nunn, Switzerland MDR and XDR TB in people living with HIV: what do we know and what we still need to know by Neel Gandhi, USA Drug resistance TB and new diagnostics for people living with HIV: emerging data from FIND by Giorgio Roscigno, Switzerland Molecular epidemiology: role for transmission of MDR/XDR by Paul van Helden, South Africa Read the presentations made at the meetingKey note presentations HIV/TB overview and rationale of meeting by Diane Havlir, USA Research on TB and HIV/AIDS: Progress and Challenges by Anthony Fauci, USA Watch Dr. Fauci's plenary presentation Session I: Diagnosis and Treatment Strategies for co-treatment: first and second line ART and TB treatment by Gary Maartens, South Africa Role of TB in early mortality of people living with HIV by Mina Hosseinipour, Malawi Sub-clinical TB among people living with HIV: what does the evidence say? By Haileyesus Getahun, Switzerland The latest developments in diagnosis and management of TB IRIS: what are the gaps? By Graeme Meintjes, South Africa Session II: TB Prevention Isoniazid preventive therapy: outcome of massive scale-up among miners in South Africa by Gavin Churchyard, South Africa TB infection control among people living with HIV: what do we know? By rod Escombe, UK Impact of ART on TB Prevention by Robin Wood, South Africa TB diagnosis in the community: approaches and outcomes by Helen Ayles, Zambia TB/HIV at CROI 2009The Stop TB Department of WHO in collaboration with the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE) organized a meeting affiliated with the 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009) in Montreal, Canada. This is the third in a series of meetings organized since 2007. The meetings have successfully raised the profile of HIV/TB among HIV researchers in particular by sharing data from ongoing studies, identifying research gaps and stimulating further HIV/TB research. The main objective of the meeting at CROI 2009 was to promote high level scientific interchange of ideas and research priorities to have a better understanding of the magnitude and burden of TB (including drug resistant strains) especially in HIV prevalent settings. List of participantsRead the presentations made at the meeting |
